Exposure to sex hormones is a major risk factor for breast cancer and current treatments include hormone modifying drugs, among them aromatase inhibitors. We studied the association of CYP19 ( 
Introduction
Breast cancer is one of the leading causes of cancer morbidity and mortality worldwide (1) . In the past decade, two major genes have been shown to be related to breast (and ovarian) cancer susceptibility, BRCA1 and BRCA2 (2) . Three Ashkenazi Jewish founder mutations in these genes (BRCA1: 185delAG and 5382insC and BRCA2: 6174delT) have a combined frequency of 2.5% in the Ashkenazi population and appear in f10% (3-5) of breast cancer cases in Ashkenazi Jewish women. Estimates of penetrance vary greatly across different studies, ranging from 37% to 90% (6) (7) (8) (9) (10) (11) (12) . This heterogeneity in risk among women who carry BRCA1/2 mutations suggests the existence of modifying genetic and/or environmental factors. Polymorphisms in several genes have been suggested to modify breast and ovarian cancer risk in BRCA1 and BRCA2 carriers, although most have not been replicated (13) (14) (15) (16) (17) (18) (19) (20) (21) . The only confirmed BRCA2 breast cancer risk modifier is RAD51 135G>C (22) . No studies have, as yet, evaluated the association between polymorphisms in the genes involved in estrogen metabolism and breast cancer risk in BRCA mutation carriers.
Because estrogens play an important role in carcinogenesis and progression of breast cancer (23, 24) , genes encoding for enzymes involved in estrogen biosynthesis and metabolism are plausible candidates as breast cancer susceptibility genes. One such candidate is CYP19 (p450arom), which encodes for aromatase, an enzyme that converts androgens to estrogens. The association of polymorphisms in the CYP19 with breast cancer risk has previously been studied, with particular focus on the [TTTA] n repeats polymorphism (25) (26) (27) (28) (29) (30) (31) . A single study observed a slightly higher [TTTA] 7 allele frequency among breast cancer cases in the Caucasian population (31) . In this study, the allele A of the silent variant at exon 3 (27, 29) .
Several studies have observed an association between CYP19 polymorphisms and concentrations of serum circulating estrogen-related metabolites. >9 , rs727479(T), rs10046(T), and rs4646(G) were associated with higher levels of estrogens (27, (35) (36) (37) (38) (39) . The Val 80 (rs700518) G allele was found to be associated with elevated aromatase expression (40) .
Estrogen receptor (ER) status is an important prognostic factor of breast tumors. A higher prevalence of ER-negative breast tumors in BRCA1 carriers was described (41) . It has been shown that this association is neither a consequence of the young age at onset nor high grade but is an intrinsic property of BRCA1-related cancers (42) . Recent studies found a significant association of the CYP19 [TTTA] 7 (delTCT) allele with ERpositive and CYP19 Trp 39 Arg (TC/CC) genotypes with ER-negative breast tumors (32, 43) .
Previous genotyping efforts established the LD haplotype block structure of CYP19 (44). In block 4, which spans the entire coding region of CYP19, four common haplotypes cover 88% of haplotype diversity in Caucasians and can be distinguished by only three single nucleotide polymorphisms (SNP; rs727479, rs10046, and rs4646). None of these haplotypes was found to be significantly associated with breast cancer risk in a large multiethnic case-control study (44) , but individual alleles rs727479(T), rs10046(T), and rs4646(G) were shown to be in association with elevated estrogen levels in postmenopausal women (39) .
The present study investigates the causality of breast cancer in the unique population of Ashkenazi Jewish women, some of which carry the BRCA1 and BRCA2 founder mutations. Based on the previously published data concerning the role of CYP19 polymorphisms in breast cancer predisposition, it was hypothesized that the Val 80 polymorphism, the [TTTA] n repeat polymorphism, or specific haplotypes in the CYP19 coding region can modify breast cancer risk. The aim of the study is to determine the clinical value of CYP19 polymorphisms in assessing breast cancer risk and their interaction with known genetic risk factors.
Materials and Methods
Study Population. The study population included 474 Ashkenazi Jewish women (223 breast cancer cases 251 healthy controls) carrying Jewish founder mutations in the BRCA1 and BRCA2 genes and 1,415 Ashkenazi Jewish noncarrier women (733 cases and 680 controls; Table 1 ). Carriers were determined to have one of the three Jewish founder mutations in BRCA1 (185delAG and 5382insC) or BRCA2 (6174delT) and were cared for by the Clalit Health Services National Familial Cancer Consultation Service at the time of study. The series of 1,405 noncarriers derived from an ongoing populationbased case-control study of the molecular and environmental etiology of breast cancer in Israel. In this study, which was initiated in 2000, all incident breast cancer cases in a distinct geographic region in Northern Israel are invited to participate after signing an informed consent approved by the Carmel Medical Center Institutional Review Board Committee. Controls are randomly sampled from the list of all women enrolled in the healthcare program provided by Clalit Health Services, the largest health services provider in Israel covering the majority of the Israeli population, and matched on age, residence, and Jewish/Arab status. Participants are interviewed by trained nurses to evaluate risk factors, including a detailed three-generation family history of cancer. Blood is drawn from each subject for DNA extraction and molecular analysis, including BRCA1 and BRCA2 founder mutation genotyping. DNA extracted from the blood is studied for a variety of molecular events, among them the existence of one or more of the Jewish founder mutations in the BRCA1 and BRCA2 genes. Participants who are found to be BRCA carriers are referred to the Clalit Health Services National Familial Cancer Consultation Service. This Service is a referral center, which can be approached by the population at large or by health professionals for advice. Most women who are evaluated by this service with regards to the breast/ovary syndromes either have a significant family history or have a personal history of breast cancer appearing at an early age, bilateral breast cancer, or breast cancer appearing in conjunction with ovarian cancer. Medical records were extracted, when available, for all study participants with breast cancer. Clinical data extracted from these records includes the ER and progesterone receptor status of the primary tumor when available.
The carriers group included 474 carriers of Jewish founder mutations: 296 of BRCA1 (218 of 185delAG and 78 of 5382insC) and 178 of BRCA2 (6174delT). Carriers with ovarian cancer only and two compound heterozygotes with mutations in both BRCA genes were not included into this study. DNA Extraction and Genotyping. Genomic DNA was extracted from whole blood using a commercially available kit according to the manufacturer's protocol (Puregene DNA extraction kit; Gentra Systems). Genetic testing for BRCA1 (185delAG and 5382insC) and BRCA2 (6174delT) was done using the Pronto BRCA kit (Pronto). Genomic DNA from breast cancer patients known to carry one of the three mutations (185delAG, 5382insC, and 6174delT) served as positive controls for each assay. All positive samples were confirmed by restriction enzyme digestion as described previously (4) .
The genotyping of CYP19 rs727479 (C_4749_10), Val 80 (rs700518; C_8794675_10), rs10046 (C_8234731_1_), and rs4646 (C_8234730_1_) was done by allelic discrimination using the 5 ¶-nuclease Assay-on-Demand on 7900HT sequence detection system (Applied Biosystems). The assay was done in a 15 AL reaction volume containing 1Â TaqMan The region of [TTTA] n repeats was amplified by PCR using the following primers: TTTA-F 5 ¶-GCAGG-TACTTAGTTAGCTAC-3 ¶ and TTTA-R 5 ¶-TTACAGT-GAGCCAAGGTCGT-3 ¶. The PCR was carried out in a total volume of 25 AL containing 3 AL DNA template (f50 ng), 10 pmol of each primer, and 1 unit Taq polymerase (TaKaRa). The reaction was incubated at 95jC for 5 min before 30 cycles of denaturation of 30 s at 95jC, annealing of 1 min at 55jC, and extension of 30 s at 72jC followed by a final extension of 10 min at 72jC. The amplified products were run on 2% agarose gels, excised, and purified by Qiagen MinElute Gel Extraction Kit (Qiagen The carriers group included 474 women clustered in 341 families. To take into account the possible correlations within these families, we applied logistic regression models for correlated data (GEE model, SAS Genmod). As these additional analyses gave similar results to the ordinary logistic regression results, only the latter are presented.
The distribution of [TTTA] alleles was compared between cases and controls using Pearson m 2 test and Armitage's trend test. Exact test was employed when appropriate. Logistic regression based on allelic data was used to estimate ORs per 1 repeat increase. For this purpose, number of repeats was considered as a continuous variable and the associated P value was reported as P trend . When the global test for association was significant, allelic OR of a specific We used the haplo.stats package (45) for R for reconstruction of haplotypes and analysis of their potential association with breast cancer. Haplotype frequencies were estimated and compared using age-adjusted global and haplotype-specific score tests (''haplo.score'' function). Rare haplotypes (combined frequency <10%) were pooled. In addition, based on inferred haplotype data, possible haplotype pairs and their posterior probability were calculated using the haplo.em function in R. A continuous variable counting the number of haplotype copies as well as indicator variables for one and two copies were created. Expectations of these variables were computed for each subject to account for the haplotype ambiguity. Using logistic regression, expected haplotype values were used to estimate age-adjusted ORs in both log-additive and dominant model. Pairwise LD (D ¶ and r 2 ) between the haplotype-tagging SNPs was tested using the m 2 statistic for LD in the ''genetic'' package for R.
In all analyses, P values < 0.05 were considered statistically significant. Unless otherwise specified, all results are age-adjusted. Analyses were done in SPSS (version 14) and SAS (version 9.1).
Results
The frequency of the CYP19 Val 80 G allele among controls was 50% in BRCA1 carriers, 50% in BRCA2 carriers, and 49% in noncarriers. CYP19 genotypes did not deviate from the Hardy-Weinberg equilibrium in controls.
In all BRCA1 mutation carriers, CYP19 Val 80 was not associated with breast cancer risk (OR per G allele increase, 1.17; 95% CI, 0.83-1.63; P = 0.370). However, it was found that, among the 180 BRCA1 carriers ages <50 years, the Val 80 G allele was associated with increased breast cancer risk (P trend = 0.028; G/G versus A/A; OR, 2.81; 95% CI, 1.09-7.22; P = 0.032; Table 2 ). No significant association between CYP19 Val 80 and breast cancer risk was found in either BRCA1 carriers of older age (age z50 years; P trend = 0.321) or BRCA2 carriers (P trend = 0.888 and 0.946 for ages <50 and z50 years, respectively; Table 2 ). There was no difference between cases and controls in Val 80 genotype distribution among the noncarriers of BRCA1/2 mutations (P trend = 0.300, 0.628, and 0.346 for the overall and ages <50 and z50 years, respectively; Table 2 ). Of the 956 breast cancer cases in the study, ER status was available for 772 (81%) cases (108 BRCA1 carriers, 55 BRCA2 carriers, and 609 noncarriers). There were 18 (2.9%) tumors diagnosed with ductal carcinoma in situ. Tumors were ER-negative in 67% of the BRCA1 carriers (72 of 108), 29.1% of the BRCA2 carriers, and 20.4% of the noncarriers. A case-only analysis of BRCA1 carriers ages <50 years showed a trend toward association between Val 80 G/G and ER-negative tumors although not statistically significant (G/G versus A/A; OR, 3.53; 95% CI, 0.58-21.51; P = 0.171; P trend = 0.173; Table 3 ).
We genotyped haplotype-tagging SNPs in haplotype block 4 covering the CYP19 coding region [rs727479, rs700518 (Val 80 ), rs10046, and rs4646] and reconstructed haplotypes. Haplotype analysis of the younger BRCA1 carriers showed an increase trend in breast cancer risk associated with the common TGTG haplotype (frequency, 48.1%; OR per haplotype copy, 1.56; P trend = 0.066; OR for TGTG haplotype homozygotes versus no copies of TGTG, 2.42; 95% CI, 0.95-6.16; P = 0.063; Table 4 ). This is consistent with the suggestive association between the rs10046 T allele and risk of breast cancer among younger BRCA1 carriers (P trend = 0.062; OR for T/T versus C/C, 2.46; 95% CI, 0.96-6. 13 allele was not found in our sample. Among the younger BRCA1 mutation carriers, increasing number of repeats tended to be associated with increased breast cancer risk (OR per 1 repeat increase, 1.18; P = 0.053; data not shown).
Discussion
In the present study, we found an association between SNPs and haplotypes of the CYP19 gene and breast cancer risk in BRCA1 mutation carriers ages <50 years. Although many studies have been published supporting the role of CYP19 polymorphisms in breast cancer (26, 27, 29, (31) (32) (33) , the modifying effect of these polymorphisms on BRCA1-related breast cancer risk had not been previously studied. Our finding may shed light on possible mechanisms by which the penetrance of BRCA mutations is altered. Such partial penetrance reflects the possible existence of modifying genes or lifestyle factors that have been formerly suggested (46) .
The previously reported prevalence of ER-negative tumors in premenopausal BRCA1 breast cancer (42) and relatively high frequency of breast cancer in the general population may bring to conclusion about higher frequency of phenocopies among women with postmenopausal breast cancer. From this point of view, the association shown in our study of CYP19 polymorphisms with breast cancer risk among premenopausal women is reasonable. In addition, a recent study found the association of CYP19 rs10046 T/T with elevated breast cancer risk in middle age group (ages 45-54 years; ref. 47 ).
The association of CYP19 with breast cancer risk was found in BRCA1 carriers ages <50 years but not in BRCA2 carriers. This agrees with known biological and clinical differences between breast tumors in BRCA1 and BRCA2 carriers (2). BRCA1-related tumors are more commonly ER-negative, differently related to reproductive risk factors, less often detected by mammography, and more commonly involve ovarian cancers than are BRCA2-related tumors. These differences may be attributed to differences in estrogen metabolism or availability.
The Suitability for hormonal chemoprevention or treatment with selective ER modulators or aromatase inhibitors is another implication of the potential association between Val 80 and ER status. Whereas most studies show that ER-negative tumors do not respond to hormonal interventions, one case-control study (48) in BRCA carriers suggested the opposite. The role of estrogen in BRCA1-related breast cancer pathogenesis (and not in BRCA2) may depend on the direct carcinogenic effect of estrogen metabolites and not on ER binding (49) . The ER-negative breast stem cells are surrounded by ERpositive cells that can exert a paracrine effect on these stem cells (49, 50) . BRCA1 is potentially involved in the maturation of ER-negative stem cells into mature ER-positive cells (42) . In BRCA1 mutation carriers, the differentiation is impaired (51) and the enlarged pool of stem cells has greater chance of malignant transformation. The higher estrogen levels potentially associated with the Val 80 G/G genotype can promote the synthesis of growth factors (such as epidermal growth factors and insulin-like growth factors) by ER-positive mature breast cells surrounding ER-negative stem cells (52) . Growth factors could further enhance stem cells proliferation, which in turn could increase the rate of stem cell transformation.
In spite of the demonstrated modifying effect of Val 
